---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-25-000048"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:01:32.845902+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q2 revenue down 5% ex-litigation; net income $34.5M; acquires Scale Bio for $30M

## Summary
- Total revenue $172.9M including $27.3M patent settlement; adjusted revenue $145.6M (-5% YoY).
- GAAP net income $34.5M vs net loss $37.9M YoY; operating income $30.1M.
- Gross margin 72% vs 68% YoY; ex-license/royalty gross margin 67%.
- Q3 2025 revenue guidance $140M-$144M, reflecting ~$4M China pull-forward.
- Agreement to acquire Scale Biosciences for $30M upfront cash/stock plus milestone contingent consideration.

## SEC filing metadata
- accession: 0001770787-25-000048
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000048/0001770787-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000048/txg-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-25-000048
- JSON: https://secwatch.observer/filing/0001770787-25-000048.json
- Plain text: https://secwatch.observer/filing/0001770787-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.